Quest Diagnostics Stock - Analyst consensus and valuation snapshot

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 13:58 UTC. Details in the imprint.

Quest Diagnostics (US74834L1008) remains a core US diagnostics player with a broadly stable analyst view and solid valuation metrics according to current market data. The stock has been trading in the upper half of its 52-week corridor, based on recent exchange figures.

What recent data show

Quest Diagnostics stock trades on the New York Stock Exchange under the ticker DGX and most recently closed near $195, placing it comfortably above the mid-point of its 52-week range according to recent quote data from MarketBeat.

On that basis, the company’s equity value implies a multi-billion dollar market capitalization, keeping Quest Diagnostics firmly within the large-cap segment of the US healthcare and diagnostics universe.

Analyst consensus and valuation

Analyst tracking compiled by MarketBeat points to a predominantly "Hold" consensus on Quest Diagnostics shares, with a modest spread between the lowest and highest published price targets.

These targets cluster not far from the current market price, which suggests that, on balance, the sell-side currently expects neither a dramatic rerating nor a sharp devaluation of the stock based on present fundamentals.

Long-term positioning in diagnostics

Quest Diagnostics operates a nationwide network of laboratories and patient service centers in the United States, providing routine lab tests, advanced diagnostics and related services to physicians, hospitals, employers and health plans according to company disclosures on its website.

This scale, combined with long-standing payer relationships, underpins the group’s long-term business model, which aims to generate steady cash flows from high-volume testing while expanding into higher-value specialty diagnostics and digital health offerings.

The product behind the stock

One representative offering from Quest Diagnostics is its comprehensive blood testing panels, which combine multiple routine tests such as cholesterol levels, blood counts and metabolic markers into single ordered panels for preventive care and chronic-disease management.

Where the stock trades today

The shares of Quest Diagnostics (US74834L1008) trade on the New York Stock Exchange at around $195 as of 06/18/2026, 15:59 Eastern Time, based on recent closing data.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.